Health Insurer Recommends RSV Prevention for Infants - New RSV vaccine guidelines target infants and elderly amid persistent outbreaks

Health authorities are urging stronger protection against respiratory syncytial virus (RSV) as cases persist. The Standing Committee on Vaccination (STIKO) has updated its recommendations for at-risk groups. Infants and older adults remain particularly vulnerable to severe illness from the infection.

STIKO now advises that all infants receive the monoclonal antibody nirsevimab during their first RSV season. This follows reports of around 700 cases among insured babies in 2024 across Saarland, Rhineland-Palatinate, and Hesse. While exact nationwide figures are unavailable, national data from early 2024 showed 1,670 cases in early January, rising to 2,675 later that month—mostly in children under four.

Hospitalisations among newborns have dropped by half in the 2024/2025 season, thanks to preventive measures. Yet RSV still poses a serious risk, potentially causing severe lower respiratory tract diseases. The virus spreads through droplets, making hygiene and isolation critical for those infected.

Older adults are also at risk. STIKO now recommends RSV vaccination for everyone aged 75 and above. IKK Südwest, which insures about 600,000 people in the region, supports these measures. Authorities stress that even now, prevention remains essential to curb transmission.

The updated guidelines aim to shield the most vulnerable from RSV's worst effects. With cases still circulating, vaccination and hygiene measures are key to reducing infections. Those showing symptoms are advised to stay away from communal spaces until fully recovered.